LinkOPH

LAS VEGAS — Two innovators who worked together to bring the latest generation of intraoperative aberrometry to surgeons were honored at the Ophthalmology Innovation Summit here.Moderator Richard L. Lindstrom, MD, said when introducing Daniel S. Durrie, MD, founder and president of Durrie Vision, and Thomas G. Frinzi, president and CEO of WaveTec Vision, as winners of the Ophthalmology Innovation Award, “It is certainly a pleasure for me, because I have known both of the winners this year for their entire careers.”

Read more →

BERNARDSVILLE, N.J.–(BUSINESS WIRE)–PanOptica briefed investors on the development of PAN-90806, a clinical-stage candidate as a topical anti-vascular endothelial growth factor eyedrop for the treatment of neovascular eye diseases.

Read more →

The FDA has accepted ThromboGenics’ investigational new drug application for the phase 2 CIRCLE study of ocriplasmin to treat nonproliferative diabetic retinopathy, according to a press release.The randomized, double-masked, sham-controlled, multicenter study will evaluate the efficacy and safety of multiple doses of Jetrea (ocriplasmin) in inducing total posterior vitreous detachment in patients with moderate to severe nonproliferative diabetic retinopathy. The trial will be conducted in the U.S. and several countries in Europe, the release said.

Read more →

Alimera Sciences reported $6.9 million in net revenue in the third quarter, a 188% increase compared with $2.4 million reported in the same quarter of 2014, according to a press release. The increase was primarily attributed to the launch of Iluvien (f…

Read more →

ANN ARBOR, Mich.–(BUSINESS WIRE)–RetroSense Therapeutics has secured $6 million in a Series B financing to further investigate the use of gene therapy and optogenetics to restore vision.

Read more →